Roche’s (RHHBY) performance in 2023 was impacted by a sharp decline in COVID-19-test sales and exchange rate fluctuations, even though newer drugs and the diagnostics base business maintained their growth. Roche has lost 8.3% in the past six months against the industry’s growth of 11.2%. Image Source: Zacks Investment Research Sales in 2023 came in at $65.4 billion, missing the Zacks Consensus Estimate of$68.2 billion. Earnings per American Depositary Receipt of $2.58 also missed the Zacks Consensus Estima ...